Literature DB >> 19721238

Enhancing effects of sericin on corneal wound healing in Otsuka Long-Evans Tokushima fatty rats as a model of human type 2 diabetes.

Noriaki Nagai1, Takatoshi Murao, Yoshimasa Ito, Norio Okamoto, Masahiro Sasaki.   

Abstract

The protein sericin is the main constituent of silk. We investigated the effects of sericin on corneal wound healing in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model for human type 2 diabetes. Corneal wounds were prepared by removal of the corneal epithelium, and documented using a TRC-50X equipped with a digital camera. Sericin solutions were instilled into the eyes of rats five times a day following corneal abrasion. Plasma glucose and triglycerides were determined using an Accutrend GCT. Cholesterol and insulin were measured using a Cholesterol E-Test Kit and ELISA Insulin Kit, respectively. The plasma levels of glucose, triglycerides, cholesterol and insulin in 38-week-old OLETF rats were significantly higher than in Long-Evans Tokushima Otsuka (LETO) rats used as normal controls, and the rate of corneal wound healing in OLETF rats was slower than in LETO rats. The corneal wounds of rats instilled with saline showed almost complete healing by 72 h after corneal epithelial abrasion. On the other hand, the corneal healing rate of OLETF rats instilled with 10% sericin solution was significantly higher than that of LETO rats instilled with saline, and the wounds showed almost complete healing at 48 h after abrasion. The corneal healing rate increased with increasing sericin concentration. The present study demonstrates that the corneal wound healing rate in OLETF rat is slower than in LETO rats, and the instillation of sericin solution has a potent effect in promoting wound healing and wound-size reduction in LETO and OLETF rats.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19721238     DOI: 10.1248/bpb.32.1594

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  8 in total

Review 1.  Therapeutic effects of sericin on diabetic keratopathy in Otsuka Long-Evans Tokushima Fatty rats.

Authors:  Noriaki Nagai; Yoshimasa Ito
Journal:  World J Diabetes       Date:  2013-12-15

Review 2.  Rodent models of diabetic nephropathy: their utility and limitations.

Authors:  Munehiro Kitada; Yoshio Ogura; Daisuke Koya
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-11-14

3.  Effects of Silk Peptides Administration on Fat Utilization Over a Whole Day in Mice.

Authors:  Jisu Kim; Jonghoon Park; Bokyung Kim; Chi-Ho Lee; Kiwon Lim; Heajung Suh
Journal:  J Exerc Nutrition Biochem       Date:  2016-12-31

4.  Oral Administration of Silk Peptide Enhances the Maturation and Cytolytic Activity of Natural Killer Cells.

Authors:  Sun-Hee Jang; Mi-Sun Oh; Hyang-Im Baek; Ki-Chan Ha; Jeong-Yong Lee; Yong-Suk Jang
Journal:  Immune Netw       Date:  2018-10-26       Impact factor: 6.303

5.  Limited Treatment Options for Diabetic Wounds: Barriers to Clinical Translation Despite Therapeutic Success in Murine Models.

Authors:  May Barakat; Luisa A DiPietro; Lin Chen
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-12-18       Impact factor: 4.947

Review 6.  Silkworm Sericin: Properties and Biomedical Applications.

Authors:  Regina Inês Kunz; Rose Meire Costa Brancalhão; Lucinéia de Fátima Chasko Ribeiro; Maria Raquel Marçal Natali
Journal:  Biomed Res Int       Date:  2016-11-14       Impact factor: 3.411

7.  Instillation of Sericin Enhances Corneal Wound Healing through the ERK Pathway in Rat Debrided Corneal Epithelium.

Authors:  Noriaki Nagai; Yuya Fukuoka; Miyu Ishii; Hiroko Otake; Tetsushi Yamamoto; Atsushi Taga; Norio Okamoto; Yoshikazu Shimomura
Journal:  Int J Mol Sci       Date:  2018-04-09       Impact factor: 5.923

8.  d-allulose protects against diabetic nephropathy progression in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes.

Authors:  Misato Niibo; Akane Kanasaki; Tetsuo Iida; Keisuke Ohnishi; Taro Ozaki; Kazuya Akimitsu; Tetsuo Minamino
Journal:  PLoS One       Date:  2022-01-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.